CS Disco (LAW) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to loss of $0.01 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 36.36%. A quarter ago, it was expected that this legal technology company would post a loss of $0.09 per share when it actually produced a loss of $0.06, delivering a surprise of 33.33%.Over the last four quarters, the company has ...

Customer Growth and Retention - As of December 31, 2024, the company had 1,478 customers, up from 1,463 in the previous year, and 315 large customers, an increase from 289[28] - The dollar-based net retention rate was 96% as of December 31, 2024, indicating strong customer loyalty and revenue growth from existing customers[21] Product Offerings and Innovation - The company’s product offerings are designed to automate legal processes, significantly reducing manual tasks and improving lawyer productivity[25] - The Cecilia AI platform, launched in Q4 2023 in the U.S. and Q3 2024 in Europe, enhances legal workflows with features like Q&A and smart timelines[25] - The company aims to pursue strategic acquisitions and investments to enhance its platform and product offerings, indicating a focus on growth through innovation[36] - The company plans to expand its product offerings to address additional areas of the legal function, anticipating increased competition in these areas[47] Financial Performance - Revenue for the year ended December 31, 2024, was $144.841 million, an increase from $138.090 million in 2023, representing a growth of approximately 5.0%[365] - The company's gross profit for 2024 was $107.427 million, compared to $103.142 million in 2023, indicating a gross margin improvement[365] - Total operating expenses increased to $169.150 million in 2024 from $152.987 million in 2023, reflecting a rise of approximately 10.6%[365] - The net loss attributable to common stockholders for 2024 was $55.774 million, compared to a loss of $42.150 million in 2023, representing an increase in losses of approximately 32.4%[365] Cash and Investments - Cash and cash equivalents were reported at $52.771 million as of December 31, 2024, down from $159.551 million in 2023[363] - The company experienced a net decrease in cash and cash equivalents of $106,780 thousand in 2024, compared to a decrease of $43,693 thousand in 2023[369] - The Company purchased $87,937 thousand in short-term investments in 2024, while there were no purchases in 2023[369] - As of December 31, 2024, the Company had $76.4 million in short-term investments, primarily in U.S. government securities[436] Research and Development - The research and development organization comprised 163 employees as of December 31, 2024[43] - The Company capitalized $2.4 million in software development costs in 2024, down from $4.3 million in 2023[439] - The Company recognized impairment charges of $1.2 million related to capitalized software development costs during the fourth quarter of 2024[440] Stock-Based Compensation and Share Repurchase - Total stock-based compensation expense for the years ended December 31, 2024 and 2023 was $22.3 million and $16.2 million, respectively[461] - The Company authorized a share repurchase program of up to $20.0 million, completing the repurchase of approximately 2.6 million shares at a weighted average price of $7.66 as of June 30, 2024[477] - The Company reversed $7.7 million in previously recognized stock-based compensation expense in September 2023 due to the termination of the CEO and cancellation of the CEO Performance Award[475] Tax and Deferred Tax Assets - The provision for income taxes for the year ended December 31, 2024, was $332,000, compared to $443,000 for 2023, reflecting a decrease in tax expenses[480] - The net deferred tax asset (liability) as of December 31, 2024, was $(127,000), compared to $(145,000) as of December 31, 2023, indicating a slight improvement[480] - The Company had a total deferred tax asset of $76.3 million and total deferred tax liabilities of $3.7 million as of December 31, 2024[480] Impairment Charges - The Company recorded a $15.2 million impairment charge in the year ended December 31, 2024, related to the primary law finite-lived intangible asset and capitalized software development costs[401] - A full non-cash impairment charge of $14.0 million was recorded for the primary law intangible asset due to zero future cash flows identified[452] - The Company recorded a $1.2 million non-cash impairment charge related to capitalized software development costs associated with the integration of the primary law intangible asset[454] Workforce and Organizational Changes - As of December 31, 2024, the Company had 151 professionals in its sales and marketing organization[41] - The Company recorded restructuring charges of $2.6 million during the year ended December 31, 2023, related to a global workforce reduction of approximately 9%[458]

Financial Performance - Fourth Quarter 2024 total revenue was $37.0 million, a year-over-year increase of 4%[2] - Software revenue for the fourth quarter was $30.8 million, up 5% compared to the fourth quarter of 2023[4] - Fiscal Year 2024 total revenue was $144.8 million, up 5% compared to fiscal year 2023[4] - Revenue for the three months ended December 31, 2024, was $36,999 million, a 3.5% increase from $35,742 million in the same period of 2023[24] - Gross profit for the year ended December 31, 2024, was $107,427 million, compared to $103,142 million in 2023, reflecting a 4.0% increase[24] - Non-GAAP gross profit for the year ended December 31, 2024, was $109,142 million, compared to $104,178 million in 2023, showing a 4.7% increase[30] Losses and Expenses - GAAP net loss for the fourth quarter was $25.2 million, compared to $5.8 million in the fourth quarter of 2023[4] - The company reported a GAAP net loss of $55.8 million for fiscal year 2024, compared to $42.2 million in fiscal year 2023[4] - Net loss attributable to common stockholders for the year ended December 31, 2024, was $55,774 million, compared to $42,150 million in 2023, indicating a 32.4% increase in losses[24] - Adjusted EBITDA for the fourth quarter was $(4.3) million, compared to $(1.0) million in the fourth quarter of 2023[4] - Adjusted EBITDA for the year ended December 31, 2024, was $(18,718) million, an improvement from $(25,894) million in 2023[30] - The operating margin for the year ended December 31, 2024, was -43%, worsening from -36% in 2023[31] - Stock-based compensation expense for the year ended December 31, 2024, was $22.27 million, up from $16.16 million in 2023[31] Customer and Product Development - The number of large customers increased to 315, up from 289 as of December 31, 2023[4] - New product features introduced include Reproductions and document-level Bates numbering[4] Future Projections - First quarter 2025 total revenue is expected to be in the range of $35.0 million - $37.0 million[4] - Fiscal year 2025 total revenue is projected to be in the range of $145.5 million - $157.5 million[4] Cash Flow and Operating Activities - Cash and cash equivalents at the end of the period were $52,771 million, a significant decrease from $159,551 million at the beginning of the period[26] - Net cash used in operating activities for the year ended December 31, 2024, was $(8,749) million, an improvement from $(25,531) million in 2023[26] Research and Development - Research and development expenses for the year ended December 31, 2024, were $51,511 million, slightly down from $51,623 million in 2023[30] - Non-GAAP research and development as a percentage of revenue for the year ended December 31, 2024, was 30%, compared to 31% in 2023[30]

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Alarum Technologies Ltd. securities, alleging that the company made false and misleading statements regarding its business performance during the specified Class Period from March 14, 2024, to August 26, 2024 [1][5]. Group 1: Lawsuit Details - The class action lawsuit claims that Alarum was less effective in retaining and expanding customer engagements than it had represented, which impaired its ability to generate consistent revenue growth [5]. - The lawsuit alleges that Alarum's business and financial prospects were overstated, leading to materially false and misleading public statements [5]. - Investors are encouraged to join the class action without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Participation Information - Interested parties can join the Alarum class action by visiting the provided link or contacting Phillip Kim, Esq. for more information [3][6]. - A lead plaintiff must move the Court by April 15, 2025, to represent other class members in directing the litigation [1][3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time and recovering hundreds of millions for investors [4]. - The firm has been consistently ranked among the top firms for securities class action settlements since 2013, securing over $438 million for investors in 2019 alone [4].

NEW YORK, Feb. 17, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Alarum Technologies Ltd. (NASDAQ: ALAR) between March 14, 2024 and August 26, 2024, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 15, 2025. SO WHAT: If you purchased Alarum securities during the ...

Group 1 - The Rosen Law Firm is reminding purchasers of Regeneron Pharmaceuticals, Inc. securities from November 2, 2023, to October 30, 2024, about the March 10, 2025, lead plaintiff deadline for a class action lawsuit [1] - Investors who purchased Regeneron securities during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties can join by contacting the Rosen Law Firm [3][6] Group 2 - The lawsuit alleges that Regeneron made false and misleading statements regarding its pricing practices for Eylea, including undisclosed credit card fee payments to distributors that affected pricing [5] - It is claimed that these undisclosed payments led to a competitive advantage for Regeneron and resulted in inflated reported sales figures for Eylea [5] - The lawsuit also asserts that Regeneron's failure to report these payments as price concessions violated the False Claims Act, misleading investors about the company's business and prospects [5] Group 3 - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4] - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone, and has been recognized for its leadership in securities class action settlements [4]

NEW YORK, Feb. 16, 2025 (GLOBE NEWSWIRE) -- WHY: New York, N.Y., February 16, 2025. Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of FMC Corporation (NYSE: FMC) between November 16, 2023 and February 4, 2025, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 14, 2025. SO WHAT: If you purchased FM ...

NEW YORK, Feb. 14, 2025 (GLOBE NEWSWIRE) -- WHY: New York, N.Y., February 14, 2025. Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Merck & Co., Inc. (NYSE: MRK) between February 3, 2022 and February 3, 2025, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 14, 2025. SO WHAT: If you purchased M ...

NEW YORK, Feb. 14, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) between November 2, 2023 and October 30, 2024, both dates inclusive (the “Class Period”), of the important March 10, 2025 lead plaintiff deadline. SO WHAT: If you purchased Regeneron securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency f ...

NEW YORK, Feb. 12, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Crocs, Inc. (NASDAQ: CROX) between November 3, 2022 and October 28, 2024, inclusive (the “Class Period”), of the important March 24, 2025 lead plaintiff deadline. SO WHAT: If you purchased Crocs common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NEXT ...